+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Deep Brain Stimulation in Parkinson's Disease Market by Device Type, Target Stimulation Site, Implantation Type, Patient Age Group, End User - Global Forecast 2026-2032- Product Image
Deep Brain Stimulation in Parkinson's Disease Market by Device Type, Target Stimulation Site, Implantation Type, Patient Age Group, End User - Global Forecast 2026-2032- Product Image
Sale

Deep Brain Stimulation in Parkinson's Disease Market by Device Type, Target Stimulation Site, Implantation Type, Patient Age Group, End User - Global Forecast 2026-2032

  • Report

  • 199 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5532737
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Deep Brain Stimulation in Parkinson’s Disease Market is projected to reach USD 1.61 Billion in 2026. It is expected to continue growing at a CAGR of 16.15%, reaching USD 4.02 Billion by 2032.

Deep brain stimulation (DBS) in Parkinson’s disease is a high-value neuromodulation field serving patients with medication-refractory motor fluctuations, dyskinesia, or tremor. The therapy is supported by decades of clinical use, randomized evidence, and guideline-based patient selection, with common surgical targets including the subthalamic nucleus, globus pallidus internus, and, for tremor-dominant cases, the ventral intermediate nucleus.

Market momentum is grounded in verified epidemiology: the World Health Organization reports that Parkinson’s disease prevalence has doubled over the past 25 years, with more than 8.5 million people living with the condition globally in 2019. For DBS device manufacturers, the opportunity is shifting from one-time implant sales toward integrated deep brain stimulation platforms combining directional leads, rechargeable implantable pulse generators, imaging-based planning, remote support, and data-enabled programming workflows.

Transformative Shifts in the DBS Landscape

The DBS landscape is being transformed by precision targeting, segmented electrodes, longer-life batteries, sensing-enabled pulse generators, and improved imaging-guided surgical planning. These shifts are improving therapeutic windows, reducing programming burden, and allowing manufacturers to differentiate through clinical workflow efficiency, patient durability, and long-term outcomes rather than hardware alone.

Regulatory expectations are also becoming more demanding. The U.S. FDA, the European Medical Device Regulation framework, and other major regulators increasingly emphasize post-market evidence, cybersecurity, software validation, human factors, and real-world performance. Companies that align product design with clinical usability, payer evidence, and long-term safety monitoring are better positioned in the Parkinson’s disease neuromodulation market.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across DBS product development, surgical planning, and post-implant optimization. Machine learning is being evaluated for imaging segmentation, lead localization, symptom-state estimation, and parameter recommendation, while adaptive DBS research uses neural signals such as local field potentials to adjust stimulation in response to changing patient states.

The commercial impact remains evidence-dependent. AI-enabled DBS tools must demonstrate clinical validity, bias control, explainability, cybersecurity resilience, and compliance with software-as-a-medical-device requirements. Manufacturers that develop AI as a clinician-supervised decision-support layer, rather than an autonomous replacement for neurologist expertise, are most aligned with current regulatory and clinical standards.

Key Regional Insights for DBS in Parkinson’s Disease

North America remains a leading region for DBS adoption because of specialized movement disorder centers, established reimbursement pathways, FDA-cleared neuromodulation platforms, and robust clinical trial infrastructure. Europe combines strong clinical expertise with the more rigorous European Medical Device Regulation, making evidence generation, vigilance, and health technology assessment essential for market access across national health systems.

Asia-Pacific is becoming a strategic growth region as Japan, South Korea, China, Australia, and India expand advanced neurology and neurosurgery capacity alongside rapidly aging populations and rising Parkinson’s disease diagnosis. Latin America shows demand in Brazil, Mexico, and major urban hospital systems but faces affordability, reimbursement, and specialist-density constraints. The Middle East, particularly high-investment Gulf health systems, is expanding advanced care and tertiary neuroscience services, while Africa remains access-limited outside select tertiary centers, creating a long-term need for training, referral pathways, and cost-sensitive DBS technologies.

Key Group Insights Across Strategic Economic Blocs

The G7 represents the most mature demand environment for DBS device manufacturers because member countries generally combine aging populations, high specialist capacity, advanced imaging infrastructure, clinical trial networks, and established reimbursement evaluation systems. The European Union is strategically important due to scale and regulatory harmonization, although national purchasing, tendering, and health technology assessment processes continue to shape adoption country by country.

BRICS markets offer large patient pools and growing neurosurgical capacity, led by China, India, and Brazil, but pricing, reimbursement, and urban-rural access gaps remain decisive. ASEAN is heterogeneous, with Singapore, Thailand, and Malaysia supporting more advanced tertiary care than lower-resource markets, while capacity building remains central in several member states. The GCC is expanding premium specialty care through public investment and medical infrastructure development, while NATO is not a healthcare purchasing bloc but includes many countries with strong neuromodulation research, data-security expectations, and advanced hospital infrastructure.

Key Country Insights in Major DBS Markets

The United States anchors global DBS commercialization through FDA-regulated innovation, extensive movement disorder networks, specialized neurosurgical centers, and strong academic trial activity. Canada supports evidence-based adoption through provincial health systems, while Mexico and Brazil show concentrated demand in major metropolitan centers where private and public tertiary care can support complex neurosurgery and post-implant programming.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have established DBS expertise, although reimbursement timing, hospital procurement, and regional access differ. Russia retains specialized neurosurgical capacity but faces broader market-access complexity. In Asia-Pacific, China is scaling domestic and international neuromodulation adoption, India combines high unmet need with affordability constraints, Japan and South Korea offer technologically advanced care with strong hospital infrastructure, and Australia benefits from specialized public and private centers serving geographically dispersed patients.

Actionable Recommendations for DBS Industry Leaders

Device leaders should prioritize differentiated clinical value: directional stimulation, battery longevity, simplified programming, MRI compatibility, remote support, patient-friendly rechargeability, and real-world outcome tracking. Evidence packages should address motor improvement, quality of life, adverse events, reoperation rates, programming time, medication reduction, patient satisfaction, and total cost of care.

Commercial teams should invest in surgeon-neurologist training, center-of-excellence partnerships, referral pathway development, and payer-ready health economics. AI-enabled features should be launched with transparent validation, clinician oversight, cybersecurity controls, interoperability planning, and post-market monitoring to build trust across regulators, hospitals, clinicians, and patients.

Research Methodology

This executive summary is based on triangulation of verified public evidence, including World Health Organization Parkinson’s disease epidemiology, peer-reviewed DBS clinical literature, Movement Disorder Society-aligned practice standards, regulator communications, and publicly available market-access information from major healthcare systems.

The analysis emphasizes evidence-backed drivers rather than speculative market sizing. Regional, group, and country insights were assessed through disease burden, aging demographics, neurosurgical capacity, reimbursement maturity, regulatory requirements, technology readiness, clinical infrastructure, and observed adoption patterns in advanced movement disorder care.

Conclusion

DBS remains one of the most established advanced therapies for appropriately selected Parkinson’s disease patients whose symptoms are not adequately controlled with medication. The market is moving toward precision neuromodulation platforms supported by better imaging, sensing, software, programming efficiency, and long-term evidence.

Manufacturers that combine clinically meaningful innovation with regulatory discipline, payer evidence, cybersecurity readiness, and scalable training infrastructure will be best positioned as Parkinson’s disease prevalence rises and health systems demand measurable outcomes from high-cost implantable therapies.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Deep Brain Stimulation in Parkinson’s Disease Market, by Device Type
7.1. Implantable Pulse Generators
7.1.1. Rechargeable IPGs
7.1.2. Non-rechargeable IPGs
7.2. Leads
7.2.1. Directional Leads
7.2.2. Omnidirectional Leads
7.3. Extension Kits
7.4. External Components
8. Deep Brain Stimulation in Parkinson’s Disease Market, by Target Stimulation Site
8.1. Subthalamic Nucle
8.2. Globus Pallidus Internus
8.3. Thalamus
8.4. Pedunculopontine Nucleus
9. Deep Brain Stimulation in Parkinson’s Disease Market, by Implantation Type
9.1. Unilateral DBS
9.2. Bilateral DBS
10. Deep Brain Stimulation in Parkinson’s Disease Market, by Patient Age Group
10.1. Less than 60 years
10.2. 60-75 years
10.3. Greater than 75 years
11. Deep Brain Stimulation in Parkinson’s Disease Market, by End User
11.1. Ambulatory Surgical Centers
11.2. Hospitals
11.3. Specialty Clinics
12. Asia-Pacific Deep Brain Stimulation in Parkinson’s Disease Market
13. North America Deep Brain Stimulation in Parkinson’s Disease Market
14. Latin America Deep Brain Stimulation in Parkinson’s Disease Market
15. Europe Deep Brain Stimulation in Parkinson’s Disease Market
16. Middle East Deep Brain Stimulation in Parkinson’s Disease Market
17. Africa Deep Brain Stimulation in Parkinson’s Disease Market
18. ASEAN Deep Brain Stimulation in Parkinson’s Disease Market
19. GCC Deep Brain Stimulation in Parkinson’s Disease Market
20. European Union Deep Brain Stimulation in Parkinson’s Disease Market
21. BRICS Deep Brain Stimulation in Parkinson’s Disease Market
22. G7 Deep Brain Stimulation in Parkinson’s Disease Market
23. NATO Deep Brain Stimulation in Parkinson’s Disease Market
24. United States Deep Brain Stimulation in Parkinson’s Disease Market
25. Canada Deep Brain Stimulation in Parkinson’s Disease Market
26. Mexico Deep Brain Stimulation in Parkinson’s Disease Market
27. Brazil Deep Brain Stimulation in Parkinson’s Disease Market
28. United Kingdom Deep Brain Stimulation in Parkinson’s Disease Market
29. Germany Deep Brain Stimulation in Parkinson’s Disease Market
30. France Deep Brain Stimulation in Parkinson’s Disease Market
31. Russia Deep Brain Stimulation in Parkinson’s Disease Market
32. Italy Deep Brain Stimulation in Parkinson’s Disease Market
33. Spain Deep Brain Stimulation in Parkinson’s Disease Market
34. China Deep Brain Stimulation in Parkinson’s Disease Market
35. India Deep Brain Stimulation in Parkinson’s Disease Market
36. Japan Deep Brain Stimulation in Parkinson’s Disease Market
37. Australia Deep Brain Stimulation in Parkinson’s Disease Market
38. South Korea Deep Brain Stimulation in Parkinson’s Disease Market
39. Competitive Landscape
39.1. Market Concentration Analysis, 2025
39.1.1. Concentration Ratio (CR)
39.1.2. Herfindahl Hirschman Index (HHI)
39.2. Recent Developments & Impact Analysis, 2025
39.3. Product Portfolio Analysis, 2025
39.4. Benchmarking Analysis, 2025
40. Company Profiles
40.1. Abbott Laboratories
40.2. Aleva Neurotherapeutics SA
40.3. Alpha Omega Engineering Ltd.
40.4. Beijing PINS Medical Co., Ltd.
40.5. Boston Scientific Corporation
40.6. BrainsWay Ltd.
40.7. Deep Brain Innovations LLC
40.8. Functional Neuromodulation, Ltd.
40.9. LivaNova PLC
40.10. Medtronic plc
40.11. Neuralink Corp.
40.12. Neuronetics, Inc.
40.13. NeuroPace, Inc.
40.14. NeuroSigma, Inc.
40.15. Newronika S.p.A.
40.16. PulseNeuro LLC
40.17. Renishaw PLC
40.18. Saluda Medical Pty Ltd.
40.19. Sapiens Neuro
40.20. SceneRay Corporation Ltd.
40.21. Shanghai Sinovation Medical Tech
40.22. Soterix Medical Inc.
40.23. St. Jude Medical, Inc.
List of Figures
FIGURE 1. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 23. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. GERMANY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. FRANCE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. ITALY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. SPAIN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL IMPLANTABLE PULSE GENERATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL IMPLANTABLE PULSE GENERATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL IMPLANTABLE PULSE GENERATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL RECHARGEABLE IPGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL RECHARGEABLE IPGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL RECHARGEABLE IPGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NON-RECHARGEABLE IPGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL NON-RECHARGEABLE IPGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NON-RECHARGEABLE IPGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL LEADS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL LEADS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL LEADS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL DIRECTIONAL LEADS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL DIRECTIONAL LEADS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL DIRECTIONAL LEADS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL OMNIDIRECTIONAL LEADS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL OMNIDIRECTIONAL LEADS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL OMNIDIRECTIONAL LEADS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL EXTENSION KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL EXTENSION KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL EXTENSION KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL EXTERNAL COMPONENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL EXTERNAL COMPONENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL EXTERNAL COMPONENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL SUBTHALAMIC NUCLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL SUBTHALAMIC NUCLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL SUBTHALAMIC NUCLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GLOBUS PALLIDUS INTERNUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GLOBUS PALLIDUS INTERNUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GLOBUS PALLIDUS INTERNUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL THALAMUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL THALAMUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL THALAMUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL PEDUNCULOPONTINE NUCLEUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL PEDUNCULOPONTINE NUCLEUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL PEDUNCULOPONTINE NUCLEUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL UNILATERAL DBS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL UNILATERAL DBS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL UNILATERAL DBS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL BILATERAL DBS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL BILATERAL DBS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL BILATERAL DBS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL LESS THAN 60 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL LESS THAN 60 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL LESS THAN 60 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL 60-75 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL 60-75 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL 60-75 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL GREATER THAN 75 YEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL GREATER THAN 75 YEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL GREATER THAN 75 YEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 75. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 76. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 77. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 78. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 79. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 84. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 85. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 86. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 87. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 91. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 92. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 93. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 94. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 95. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 96. LATIN AMERICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 97. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 99. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 100. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 101. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 102. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 103. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 104. EUROPE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 105. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 107. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 108. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 109. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 110. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 111. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 112. MIDDLE EAST DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 113. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 115. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 116. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 117. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 118. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 119. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 120. AFRICA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 121. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 122. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 123. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 124. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 125. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 126. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 127. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 128. ASEAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 129. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 130. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 131. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 132. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 133. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 134. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 135. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 136. GCC DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 138. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 139. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 140. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 141. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 142. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 143. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 144. EUROPEAN UNION DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 145. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 146. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 147. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 148. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 149. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 150. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 151. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 152. BRICS DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 153. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 154. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 155. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 156. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 157. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 158. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 159. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 160. G7 DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 161. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 162. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 163. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 164. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 165. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 166. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 167. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 168. NATO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 169. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 170. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 171. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 172. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 173. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 174. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 175. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 176. UNITED STATES DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 177. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 178. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 179. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 180. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 181. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 182. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 183. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 184. CANADA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 185. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 186. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 187. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 188. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 189. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 190. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 191. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 192. MEXICO DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 193. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 194. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 195. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 196. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 197. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 198. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 199. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 200. BRAZIL DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 201. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 202. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 203. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 204. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 205. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 206. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 207. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 208. UNITED KINGDOM DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 209. GERMANY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 210. GERMANY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 211. GERMANY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 212. GERMANY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 213. GERMANY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 214. GERMANY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 215. GERMANY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 216. GERMANY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 217. FRANCE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 218. FRANCE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 219. FRANCE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 220. FRANCE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 221. FRANCE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 222. FRANCE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 223. FRANCE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 224. FRANCE DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 225. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 226. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 227. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 228. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 229. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 230. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 231. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 232. RUSSIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 233. ITALY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 234. ITALY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 235. ITALY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 236. ITALY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 237. ITALY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 238. ITALY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 239. ITALY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 240. ITALY DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 241. SPAIN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 242. SPAIN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 243. SPAIN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 244. SPAIN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 245. SPAIN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 246. SPAIN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 247. SPAIN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 248. SPAIN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 249. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 250. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 251. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 252. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 253. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 254. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 255. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 256. CHINA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 257. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 258. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 259. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 260. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 261. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 262. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 263. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 264. INDIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 265. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 266. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 267. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 268. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 269. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 270. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 271. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 272. JAPAN DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 273. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 274. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 275. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 276. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 277. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 278. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 279. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 280. AUSTRALIA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 281. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 282. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
TABLE 283. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTABLE PULSE GENERATORS, 2018-2032 (USD MILLION)
TABLE 284. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY LEADS, 2018-2032 (USD MILLION)
TABLE 285. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY TARGET STIMULATION SITE, 2018-2032 (USD MILLION)
TABLE 286. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY IMPLANTATION TYPE, 2018-2032 (USD MILLION)
TABLE 287. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
TABLE 288. SOUTH KOREA DEEP BRAIN STIMULATION IN PARKINSON’S DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Deep Brain Stimulation in Parkinson’s Disease market report include:
  • Abbott Laboratories
  • Aleva Neurotherapeutics SA
  • Alpha Omega Engineering Ltd.
  • Beijing PINS Medical Co., Ltd.
  • Boston Scientific Corporation
  • BrainsWay Ltd.
  • Deep Brain Innovations LLC
  • Functional Neuromodulation, Ltd.
  • LivaNova PLC
  • Medtronic plc
  • Neuralink Corp.
  • Neuronetics, Inc.
  • NeuroPace, Inc.
  • NeuroSigma, Inc.
  • Newronika S.p.A.
  • PulseNeuro LLC
  • Renishaw PLC
  • Saluda Medical Pty Ltd.
  • Sapiens Neuro
  • SceneRay Corporation Ltd.
  • Shanghai Sinovation Medical Tech
  • Soterix Medical Inc.
  • St. Jude Medical, Inc.

Table Information

Report AttributeDetails
No. of Pages199
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.61 Billion
Forecasted Market Value ( USD ) by 2032 $ 4.02 Billion
Compound Annual Growth Rate16.1%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Deep Brain Stimulation in Parkinson's Disease - Global Strategic Business Report - Product Image

Deep Brain Stimulation in Parkinson's Disease - Global Strategic Business Report

  • Report
  • 274 Pages
  • Global
From
Deep Brain Stimulation Devices Market by Product Type, Component, Waveform, Battery Type, Application, End User, Distribution Channel - Global Forecast 2026-2032 - Product Image

Deep Brain Stimulation Devices Market by Product Type, Component, Waveform, Battery Type, Application, End User, Distribution Channel - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Deep Brain Stimulation in Parkinson`s Disease Market Report 2026 - Product Image

Deep Brain Stimulation in Parkinson`s Disease Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Deep Brain Stimulation Devices Market Analysis (2026-2031): Neurotech Innovations, Supply Chain Dynamics, and Strategic Intelligence - Product Image

Deep Brain Stimulation Devices Market Analysis (2026-2031): Neurotech Innovations, Supply Chain Dynamics, and Strategic Intelligence

  • Report
  • 95 Pages
  • Global
From
Deep Brain Stimulation Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Deep Brain Stimulation Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From

About the Deep Brain Stimulation In Parkinson Disease Market

Deep brain stimulation (DBS) for Parkinson's disease is a therapeutic procedure aimed at managing the symptoms of this neurodegenerative disorder when medication is insufficient or leads to undesirable side effects. This method involves the surgical implantation of electrodes within certain areas of the brain, generating electrical impulses that regulate abnormal impulses. The DBS devices are an integral part of the Central Nervous System (CNS) drugs and devices domain, which encompasses a broad range of therapies for various neurological conditions, including medication, neuromodulation devices, and support services. Within this context, DBS acts as an adjunct to pharmacological treatments, offering an alternative for patients with advanced Parkinson's disease. While CNS drugs typically address the dopaminergic deficits inherent to Parkinson's disease pathophysiology through oral or injectable medications, DBS provides a unique mechanistic approach by directly modulating brain activity and circuits involved in motor control. The procedure is generally reserved for patients exhibiting motor fluctuations and tremors that are not adequately controlled by medication. Several industry players are active in the DBS market for Parkinson's disease. Key companies engaged in the development and provision of DBS systems include Medtronic, Boston Scientific, and Abbott Laboratories. These entities continuously engage in research and development to advance the technology, increase its efficacy, and reduce any associated risks, thereby improving the lives of patients with Parkinson's disease. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.